Method for inducing experimental pneumococcal meningitis in outbred mice

BMC Microbiology

Volumn 4, Issue , 2004, Pages

  Chiavolini, Damiana ^a,b   Tripodi, Sergio ^a   Parigi, Riccardo ^a   Oggioni, Marco R ^a   Blasi, Elisabetta ^c   Cintorino, Marcella ^a   Pozzi, Gianni ^a   Ricci, Susanna ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR FONTANEL; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM COLONY; BLOOD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DYING; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; MOUSE; NONHUMAN; OUTBRED STRAIN; REPRODUCIBILITY; SEROTYPE; SPLEEN; STREPTOCOCCUS PNEUMONIAE; SUBARACHNOID SPACE; SURVIVAL RATE;

ANIMALS; BACTEREMIA; BRAIN; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS; MENINGITIS, PNEUMOCOCCAL; MICE; SEROTYPING; SPLEEN; STREPTOCOCCUS PNEUMONIAE; SUBARACHNOID SPACE; SURVIVAL ANALYSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 8844232717     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-4-36     Document Type: Article

References (57)

1. Leib SL, Tauber MG: Pathogenesis of bacterial meningitis. Infect Dis Clin North Am 1999, 13:527-548.
2. Koedel U, Scheld W, Pfister H-W: Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002, 2:721-736.
3. van de Beek D, Schmand B, de Gans J, Weisfelt M, Vaessen H, Dankert J, Vermeulen M: Cognitive impairment in adults with good recovery after bacterial meningitis. J Infect Dis 2002, 186:1047-1052.
4. Obaro S, Adegbola R: The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002, 51:98-104.
5. Van Ginkel FW, McGhee JR, Watt JM, Campos-Torres A, Parish LA, Briles DE: Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci USA 2003, 100:14363-14367.
6. Tsai YH, Bies M, Leitner F, Kessler RE: Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats. Antimicrob Agents Chemother 1990, 34:733-738.
7. Pfister HW, Koedel U, Haberl RL, Dirnagl U, Feiden W, Ruckdeschel G, Einhaupl KM: Microvascular changes during the early phase of experimental bacterial meningitis. J Cereb Blood Flow Metab 1990, 10:914-922.
8. Leib SL, Leppert D, Clements J, Tauber MG: Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 2000, 68:615-620.
9. Hirst RA, Gosai B, Rutman A, Andrew PW, O'Callaghan C: Streptococcus pneumoniae damages the ciliated ependyma of the brain during meningitis. Infect Immun 2003, 71:6095-6100.
10. Dacey RG, Sande MA: Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974, 6:437-441.
11. Lindquist L, Lundbergh P, Hedstrom KG, Hansson LO, Hultman : Experimental bacterial meningitis in the rabbit: cerebrospinal fluid changes and its relation to leukocyte response. Scand J Infect Dis 1987, 19:263-270.
12. Bhatt S, Halpin C, Hsu W, Thedinger BA, Levine RA, Tuomanen E, Nadol JBJ: Hearing loss and pneumococcal meningitis: an animal model. Laryngoscope 1991, 101:1285-1292.
13. Nau R, Kaye K, Sachdeva M, Sande ER, Tauber MG: Rifampin for therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1994, 38:1186-1189.
14. Rodriguez AF, Kaplan SL, Hawkins EP, Mason EOJ: Hematogenous pneumococcal meningitis in the infant rat: description of a model. J Infect Dis 1991, 164:1207-1209.
15. Tan TQ, Wayne Smith C, Hawkins EP, Mason EOJ, Kaplan SL: Hematogenous bacterial meningitis in an intercellular adhesion molecule-1-deficient infant mouse model. J Infect Dis 1995, 171:342-349.
16. Iizawa Y, Hiroe K, Nakao M, Okonogi K: Therapeutic efficacy of cefozopran in a murine model of haematogenous pneumococcal meningitis. Chemotherapy 1998, 44:265-271.
17. Tsao N, Chang WW, Liu CC, Lei HY: Development of hematogenous pneumococcal meningitis in adult mice: the role of TNF-α. FEMS Immunol Med Microbiol 2002, 32:133-140.
18. Marra A, Brigham D: Streptococcus pneumoniae causes experimental meningitis following intranasal and otitis media infections via a non hematogenous route. Infect Immun 2001, 69:7318-7325.
19. Zwijnenburg PJG, van der Poll T, Florquin S, van Deventer SJH, Roord JJ, van Furth AM: Experimental pneumococcal meningitis in mice: a model of intranasal infection. J Infect Dis 2001, 183:1143-1146.
20. Tsai YH, Williams EB, Hirth RS, Price KE: Pneumococcal meningitis-therapeutic studies in mice. Chemotherapy 1975, 21:342-357.
21. Gerber J, Raivich G, Wellmer A, Noeske C, Kunst T, Werner A, Brück W, Nau R: A mouse model of Streptococcus pneumoniae meningitis mimicking several features of human disease. Acta Neuropathol 2001, 101:499-508.
22. Shapiro MA, Donovan KD, Gage JW: Comparative efficacy of clinafloxacin in a pneumococcal meningitis mouse model. J Antimicrob Chemother 2000, 45:489-492.
23. Koedel U, Paul R, Winkler F, Kastenbauer S, Huang PL, Pfister HW: Lack of endothelial nitric oxide synthase aggravates murine pneumococcal meningitis. J Neuropathol Exp Neurol 2001, 60:1041-1050.
24. Zwijnenburg PJG, van der Poll T, Florquin S, Akira S, Takeda K, Roord JJ, van Furth AM: Interleukin-18 gene-deficient mice show enhanced defense and reduced inflammation during pneumococcal meningitis. J Neuroimmunol 2003, 138:31-37.
25. Zwijnenburg PJG, van der Poll T, Florquin S, Roord JJ, van Furth AM: Interleukin-10 negatively regulates local cytokine and chemokine production but does not influence antibacterial host defense during murine pneumococcal meningitis. Infect Immun 2003, 71:2276-2279.
26. Zwijnenburg PJG, van der Poll T, Florquin S, Roord JJ, van Furth AM: IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. J Immunol 2003, 170:4724-4730.
27. Wellmer A, Zysk G, Gerber J, Kunst T, von Mering M, Bunkowski S, Eiffert H, Nau R: Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis. Infect Immun 2002, 70:6504-6508.
28. Böttcher T, Spreer A, Azeh I, Nau R, Gerber J: Matrix metalloproteinase-9 deficiency impairs host defense mechanisms against Streptococcus pneumoniae in a mouse model of bacterial meningitis. Neurosci Lett 2003, 338:201-204.
29. Koedel U, Winkler F, Angele B, Fontana A, Flavell RA, Pfister HW: Role of caspase-1 in experimental pneumococcal meningitis: evidence from pharmacologic caspase inhibition and caspase-1-deficient mice. Ann Neurol 2002, 51:319-329.
30. phox deficiency on the course of pneumococcal meningitis. Infect Immun 2003, 71:4087-4092.
31. Wellmer A, Gerber J, Ragheb J, Zysk G, Kunst T, Smirnov A, Bruck W, Nau R: Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect Immun 2001, 69:6881-6886.
32. Koedel U, Angele B, Rupprecht T, Wagner H, Roggenkamp A, Pfister H-W, Kirschning CJ: Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J Immunol 2003, 170:438-444.
33. Paxinos G, Franklin KBJ: The mouse brain in stereotaxic coordinates Second Deluxe edition. Academic Press; 2001.
34. Avery OT, MacLeod CM, McCarty M: Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of tranformation by a desoxyribonucleic acid fraction isolated from Pneumococcus type III. J Exp Med 1944, 79:137-158.
35. Iannelli F, Pearce BJ, Pozzi G: The type 2 capsule locus of Streptococcus pneumoniae. J Bacteriol 1999, 181:2652-2654.
36. Pearce BJ, Iannelli F, Pozzi G: Construction of new unencapsulated (rough) strains of Streptococcus pneumoniae. Res Microbiol 2002, 153:243-247.
37. Bernheimer HP, Wermundsen IE: Unstable binary capsulated transformants in Pneumococcus. J Bacteriol 1969, 98:1073-1079.
38. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umajama LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 2001, 293:498-506.
39. Azoulay-Dupuis E, Bedos JP, Vallee E, Hardy DJ, Swanson RN, Pocidalo JJ: Antipneumococcal activity of ciprofloxacin, oxofloxacin and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis 1991, 163:319-324.
40. Canvin JR, Marvin AP, Sivakumaran M, Paton JC, Boulnois GJ, Andrew PW, Mitchell TJ: The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 1995, 172:119-123.
41. Tateda K, Takashima K, Miyazaki H, Matsumoto T, Hatori T, Yamaguchi K: Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother 1996, 40:1520-1525.
42. Iizawa Y, Kitamoto K, Hiroe K, Nakao M: Streptococcus pneumoniae in the nasal cavity of mice causes lower respiratory tract infection after airway obstruction. J Med Microbiol 1996, 44:490-495.
43. 2 fragments administered intranasally. J Infect Dis 1996, 173:1123-1128.
44. Soriano F, Ponte C, Nieto E, Parra A: Correlation of in vitro activity and pharmacokinetics parameters with in vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. J Antimicrob Chemother 1996, 38:227-236.
45. Briles DE, Nahm MH, Schroer K, Davie J, Baker P, Kearney J, Barletta R: Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med 1981, 153:694-705.
46. Wang E, Ouellet N, Simard M, Fillion I, Bergeron Y, Beauchamp D, Bergeron MG: Pulmonary and systemic host response to Streptococcus pneumoniae and Klebsiella pneumoniae bacteremia in normal and immunosuppressed mice. Infect Immun 2001, 69:5294-5304.
47. Iannelli F, Chiavolini D, Ricci S, Oggioni MR, Pozzi G: Pneumococcal surface protein C (PspC) contributes to sepsis caused by Streptococcus pneumoniae. Infect Immun 2004, 72:3077-3080.
48. Blasi E, Barluzzi R, Bistoni F, Mosci P, Bistoni : Experimental model of intracerebral infection with Cryptococcus neoformans : roles of phagocytes and opsonization. Infect Immun 1992, 60:3682-3688.
49. Pillon B, Bazin B, Deweer B, Ehrle N, Baulac M, Dubois B: Specificity of memory deficits after right or left temporal lobectomy. Cortex 1999, 35:561-571.
50. Karganov M, Romanova G, Braslawsky W, Tarshitz D, Telegdy G: Neuromodulator role of VIP in recovery of rat behavior and brain neurotransmitters level after frontal lobectomy. Ann N Y Acad Sci 1998, 865:519-522.
51. Gingles NA, Alexander JE, Kadioglu A, Andrew PW, Kerr A, Mitchell TJ, Hopes E, Denny P, Brown S, Jones HB, Little S, Booth GC, McPheat WL: Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun 2001, 69:426-434.
52. Chiavolini D, Memmi G, Maggi T, Iannelli F, Pozzi G, Oggioni MR: The three extra-cellular zinc metalloproteinases of Streptococcus pneumoniae have a different impact on virulence in mice. BMC Microbiology 2003, 3:14.
53. Carp RI, Davidson AI, Merz PA: A method for obtaining cerebrospinal fluid from mice. Res Vet Sci 1971, 12:499.
54. Greenfield JG, Lantos PL, Graham DI: Greenfield's Neuropathology 7th edition. New York; 2002.
55. Barluzzi R, Brozzetti A, Mariucci G, Tantucci M, Neglia RG, Bistoni F, Blasi E: Establishment of protective immunity against cerebral cryptococcosis by means of an avirulent, non melanogenic Cryptococcus neoformans strain. J Neuroimmunol 2000, 109:75-86.
56. Reed LJ, Muench H: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
57. Finney DJ: Probit Analysis 3rd edition. London, UK: Cambridge University Press; 1971.